43 results on '"Hutcheon, G."'
Search Results
2. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes
- Author
-
Monti, S., Craven, A., Klersy, C., Montecucco, C., Caporali, R., Watts, R., Merkel, P. A., Luqmani, R., Achilleos, K., Adler, M., Alba, M. A., Albert, D. A., Alibaz-Oner, F., Allcoat, P., Amano, K., Amarasuriya, M., Amudala, N. A., Andrews, J., Archer, A. M., Arimura, Y., Atukorala, I., Azevedo, E., Bajad, S., Baldwin, C., Barra, L. J., Baslund, B., Basu, N., Baykal, M., Berger, C., Berglin, E., Besada, E., Bhardwaj, M., Bischof, A., Blockmans, D., Blood, J., Draibe, J. B., Brand, S., Brandao, M., Bruce, I. N., Butler, A., Calabrese, L. H., Ferrer, D. C., Carette, S., Carmona, D., Ceunen, H., Chakravarty, K., Chapman, P. T., Chocova, Z., Chung, S. A., Ci, W., Cid, M. C., Clark, T. M., Clarkson, M. R., De Jesus Contreras-Rodriguez, F., Conway, R., Cooke, K., Viros, X. C., Cordeiro, A., Costa, A., Culfear, K., Daikeler, T., Danda, D., Das, S. K., Dasgupta, B., De Castro, A. M., Dehghan, N., Devassy, R., Dhindsa, N., Diamantopoulos, A. P., Direskeneli, H., Dobashi, H., Juan, D., Durrani, M., Edelsten, C., Eifert, J., Elhayek, S., Elsideeg, S., Endo, T., Erden, A., Erer, B., Eriksson, P., Erturk, Z., Espigol-Frigole, G., Felicetti, M., Ferraro, A., Ferro, J. M., Fifi-Mah, A., Flores-Suarez, L. F., Flossmann, O., Flynn, D., Fonseca, J. E., Foot, J., Foote, M., Forbess, L., Fujimoto, S., Fukuoka, K., Furtado, C., Furuta, S., Gaffo, A. L., Gallagher, P., Gao, N., Gatenby, P., Gendi, N., Geraldes, R., Gerits, A., Gioffredi, A., Gomples, L., Goncalves, M. J., Gondo, P., Graham, A., Grainger, R., Gray, D. T., Grayson, P. C., Griffiths, L., Guo, Y., Gupta, R., Gylling, M., Hajj-Ali, R. A., Hammam, N., Harigai, M., Hartley, L., Haslett, J., Hassan, A., Hatemi, G., Hellmich, B., Henckaerts, L., Henes, J. C., Hepburn, J., Herd, V., Hess, C., Hill, C., Hinojosa-Azaola, A., Hirahashi, J., Hirano, F., Hocevar, A., Holle, J., Hollinger, N., Homma, S., Howard, T., Hoyles, R. K., Hruskova, Z., Hutcheon, G., Ignacak, M., Igney-Oertel, A., Ikeda, K., Ikegaya, N., Jagadeesh, S., Jaquith, J., Jayne, D. R. W., Jewell, T., Jones, C., Joshi, A., Kalyoncu, U., Kamall, S., Kamath, S., Lai, K. S., Kaname, S., Kanchinadham, S., Karadag, O., Karube, M., Kaszuba, M., Kaur, R., Kawakami, T., Kawashima, S., Khalidi, N., Khan, A., Kikuchi, M., Kilic, L., Kimura, M., King, M. J., Klapa, S., Klocke, R., Kobayashi, T., Kobayashi, S., Komagata, Y., Kronbichler, A., Kuczia, P., Kumar, M. S., Kurosawa, M., Lamprecht, P., Langford, C. A., Lanyon, P., Laversuch, C., Lee, S. J., Leoni, S., Li, J., Liang, K., Liang, P., Liao, H., Lee, L. A., Luqmani, R. A., Lyle, A., Macdonald, M., Mackie, S. L., Madden, L., Magliano, M., Makino, H., Makol, A., Malaiya, R., Malaviya, A., Manthri, R., Maritati, F., Da Silva, A. M., Mason, J. C., Matara, C., Matsui, K., Matteson, E. L., Mcbride, D., Mccullough, K., Mcgeoch, L., Mclaren, J., Mcmillian, C., Mendiratta, N., Menon, A., Merinopoulos, D., Merkel, P., Messier, S., Micheletti, R. G., Mills, K., Milman, N., Minoda, M., Minz, R. W., Mock, C., Mohammad, A. J., Moiseev, S., Moitinho, M., Molloy, E., Monach, P. A., Montgomery, M., Moosig, F., Moradizadeh, M., Morgan, M., Morgan, A. W., Morgan, A. -M., Muir, A., Mukhtyar, C., Muller, A., Muratore, F., Muso, E., Nada, R., Nakajima, H., Nakajima, T., Nakano, H., Nandagudi, A., Neumann, T., Y. F., Ng, K. H., Ng, Nogueira, E. L., Nolkha, N., Nordstrom, D., Novikov, P., Nugaliyadde, A., O'Donnell, J. L., O'Donoghue, J., O'Neill, L., O'Riordan, E., Oatley, M., Okubo, K., Oliva, E., Oshikawa, H., Ota, Y., Padoan, R., Pagnoux, C., Pan, L., Panaritis, K., Park, J. K., Patel, S., Patil, P., Pazzola, G., Peall, A., Pearce, F., Pehlevan, S., Pereira, L., Pettersson, T., Pineau, C. A., Pirila, L., Poglodek, B., Ponte, C., Prieto-Gonzalez, S., Priya, S. R., Purewal, B., Purschke, S., Putaala, J., Quickert, S., Quincey, V., Raghuvanshi, S., Rajasekhar, L., Ranganathan, D., Rathi, M., Rees, D., Rees, F., Renken, U., Restuccia, G., Rhee, R. L., Rice, B., Robins, D., Robson, J., Rodrigues, M., Romao, V. C., Rotar, C., Ruediger, C., Rutgers, A., A. C., Sa, Saavedra, M. J., Sada, K. -E., Sahbudin, I., Salvarani, C., Sandhu, N., Santos, E., Sato, Y., Schafer, V. S., Schiavon, F., Schmidt, W. A., Segelmark, M., Shahin, A., Sharma, A., Shotton, J., Silva, C., Singer, O. G., Sivasuthan, G., Smolen, S., Solanich-Moreno, X., Boixader, L. S., Song, Y. W., Springer, J., Sreih, A. G., Srivastava, R., Stamp, L. K., Stevens, R., Strbian, D., Sugino, K., Sunderkotter, C., Suppiah, R., Suzuki, K., Szekanecz, Z., Sznajd, J., Taimen, K., Tak, P. P., Takeuchi, T., Takizawa, N., Tames, L., Tan, B. E., Tanaka, M., Tang, M. W., Tatlisumak, T., Tesar, V., Thomas, A., Tian, X., Tokunaga, K., Tombetti, E., Tomsic, M., Toz, B., Tsukamoto, T., Uchida, S., Unal, A. U., Urban, M. L., Usui, J., Vaglio, A., Venkatachalam, S., Vermaak, E., Viswanath, V., Wada, T., Wagh, S., Wallace, D. J., Walters, G., Walz, B., Wan, J., Wang, T., Wang, G., Warrington, K. J., Watts, R. A., Wawrzycka-Adamczyk, K., Weeratunga, P., Weisman, M. H., Wickramasinghe, S., Williams, M., Wojcik, K., Woodruff, L., Xenitidis, T., Yamada, H., Yamagata, K., Yee, C. -S., Yoon, M., Yoshida, K., Yoshifuji, H., Ytterberg, S. R., Yumura, W., Zayed, H., Zeng, X., Zhao, M. -H., Zugaj, A., Zuk, J., İç Hastalıkları, Clinical Haematology, and Translational Immunology Groningen (TRIGR)
- Subjects
Male ,Outcome ,Antineutrophil Cytoplasmic ,030232 urology & nephrology ,0302 clinical medicine ,Risk Factors ,80 and over ,Pharmacology (medical) ,Age of Onset ,Young adult ,Aged, 80 and over ,education.field_of_study ,age ,anti-neutrophil cytoplasmic antibody-associated vasculitis ,outcome ,Adolescent ,Adult ,Aged ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Antibodies, Antineutrophil Cytoplasmic ,Female ,Humans ,Middle Aged ,Morbidity ,Prognosis ,Retrospective Studies ,Risk Assessment ,Survival Rate ,United Kingdom ,Young Adult ,Vasculitis ,Systemic vasculitis ,medicine.medical_specialty ,Population ,anti-neutrophil cytoplasmic antibody–associated vasculitis ,Antibodies ,03 medical and health sciences ,Rheumatology ,Internal medicine ,medicine ,education ,Anti-neutrophil cytoplasmic antibody–associated vasculitis ,Survival rate ,Anti-neutrophil cytoplasmic antibody ,030203 arthritis & rheumatology ,business.industry ,Retrospective cohort study ,medicine.disease ,Age of onset ,business - Abstract
Objectives ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- and older-onset patients are still incompletely understood. Methods We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: Results A total of 1338 patients with AAV were included: 66% had disease onset at Conclusion Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients.
- Published
- 2021
- Full Text
- View/download PDF
3. Nanomaterials, Nanotechnology
- Author
-
Adlakha-Hutcheon, G., primary, Khaydarov, R., additional, Korenstein, R., additional, Varma, R., additional, Vaseashta, A., additional, Stamm, H., additional, and Abdel-Mottaleb, M., additional
- Published
- 2009
- Full Text
- View/download PDF
4. Encapsulation, release, bioactivity and cytotoxicity of lysozyme loaded poly(glycerol adipte-co-ω-pentadecalactone) microparticles
- Author
-
Tawfeek, H. M., Khidr, S. H., Samy, E. M., Ahmed, S. M., Evans, A., Gaskell, E. E., and Hutcheon, G. A.
- Published
- 2010
5. Generation and characterisation of new anhydrous polymorph of theophylline
- Author
-
Khamar, D., Seton, L., Bradshaw, I., and Hutcheon, G.
- Published
- 2010
6. Pulmonary delivery of α-chymotrypsin via novel polyester microparticles
- Author
-
Tawfeek, H. M., Khidr, S. H., Samy, E. M., Ahmed, S. M., Shabir, A., Mohammed, A. R., Hutcheon, G. A., and Saleem, I.
- Published
- 2010
7. Interactions of chondrocytes with methacrylate copolymers
- Author
-
Hutcheon, G. A., Downes, S., and Davies, M. C.
- Published
- 1998
- Full Text
- View/download PDF
8. Overcoming the mucin barrier in the treatment of pulmonary cystic fibrosis: 27
- Author
-
Hutcheon, G. A., Gaskell, E., Iftikhar, A., and Rostron, C.
- Published
- 2009
- Full Text
- View/download PDF
9. Evaluation of ibuprofen-loaded microspheres prepared from novel copolyesters
- Author
-
Thompson, C. J., Hansford, D., Higgins, S., Rostron, C., Hutcheon, G. A., and Munday, D. L.
- Published
- 2007
- Full Text
- View/download PDF
10. Uptake and metabolism of novel biodegradable poly (glycerol-adipate) nanoparticles in DAOY monolayer
- Author
-
Meng, W., Parker, T. L., Kallinteri, P., Walker, D. A., Higgins, S., Hutcheon, G. A., and Garnett, M. C.
- Published
- 2006
- Full Text
- View/download PDF
11. Encapsulation of mucinolytic enzymes for treatment of cystic fibrosis: 181
- Author
-
Gaskell, E., Hobbs, G., Rostron, C., and Hutcheon, G. A.
- Published
- 2006
12. Preparation and characterisation of microspheres of a novel polyester polymer conjugated to ibuprofen: 37
- Author
-
Thompson, C. J., Hansford, D., Munday, D. L., Higgins, S., Hutcheon, G. A., and Rostron, C.
- Published
- 2006
13. Preparation and evaluation of microspheres prepared from novel polyester-ibuprofen conjugates blended with non-conjugated ibuprofen
- Author
-
Thompson, C. J., primary, Hansford, D., additional, Higgins, S., additional, Rostron, C., additional, Hutcheon, G. A., additional, and Munday, D. L., additional
- Published
- 2009
- Full Text
- View/download PDF
14. La dimensión reglamentaria de la obtención de animales por medios biotecnológicos en Canadá
- Author
-
KOCHHAR, H.P.S., primary, ADLAKHA-HUTCHEON, G., additional, and EVANS, B.R., additional
- Published
- 2005
- Full Text
- View/download PDF
15. Nanomaterials, Nanotechnology.
- Author
-
Adlakha-Hutcheon, G., Khaydarov, R., Korenstein, R., Varma, R., Vaseashta, A., Stamm, H., and Abdel-Mottaleb, M.
- Abstract
Nanotechnology is a platform technology that is finding more and more applications daily. Today over 600 consumer products are available globally that utilize nanomaterials. This chapter explores the use of nanomaterials and nanotechnology in three areas, namely Medicine, Environment and Energy. Given the large number of applications being designed that utilize nanomaterials and nanotechnologies, and the perception that nanotechnology can (or will) provide the ultimate solution for the world's problems; questions arise regarding who benefits from these technological advances. Additionally, within the popular press all nanotechnology products are generally portrayed as being beneficial to society without necessarily distinguishing between real and potential benefits of the technology. Lastly, the benefits and implications of these technological advancements in society are explored.
1 [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
16. Water absorption and surface properties of novel poly(ethylmethacrylate) polymer systems for use in bone and cartilage repair
- Author
-
Hutcheon, G, primary
- Published
- 2001
- Full Text
- View/download PDF
17. Novel Functionalized Biodegradable Polymers for Nanoparticle Drug Delivery Systems
- Author
-
Kallinteri, P., Higgins, S., Hutcheon, G. A., Pourcain, C. B. St., and Garnett, M. C.
- Abstract
We have prepared and screened a library of novel functionalized polymers for development of nanoparticle drug delivery systems. The polymer backbone consisting of two ester-linked, nontoxic, biological monomers, glycerol and adipic acid, was prepared using a hydrolytic enzyme. The specificity of the chosen enzyme yields a linear polymer with one free pendant hydroxyl group per repeat unit, which can be further functionalized. This protocol gives control over the backbone polymer molecular weight, together with the ability to incorporate various amounts of different fatty acyl substituents. These functionalized polymers are able to self-assemble into well-defined small particles of high homogeneity with a very low toxicity. They are able to incorporate a water soluble drug, dexamethasone phosphate, with a high efficiency and drug loading which varies with the polymer specification. The above characteristics strongly suggest that these polymers could be developed into useful nanoparticulate drug delivery systems.
- Published
- 2005
18. Human T-Cell Lymphotropic Virus Type III (HTLV-III) Embryopathy
- Author
-
Marion, R. W., primary, Wiznia, A. A., additional, Hutcheon, G., additional, and Rubinstein, A., additional
- Published
- 1986
- Full Text
- View/download PDF
19. Pulmonary delivery of resveratrol-loaded nanocomposite microparticles to treat lung cancer
- Author
-
Muller, A., Hutcheon, G., Fatokun, A., and Sarker, S.
- Subjects
616.99 ,RM Therapeutics. Pharmacology - Abstract
Lung cancer was a rare disease in the latter part of the 19th century, but grew into a full-scale epidemic in the 20th century, becoming the most common cause of cancer related death worldwide. Current cancer chemotherapy, involves the administration of cytotoxic drugs that kill all cells exhibiting a high rate of proliferation and regeneration, which is a characteristic of cancer cells, but also non-cancerous cells, such as hair follicles, bone marrow and gastrointestinal tract cells. Therefore, the systemic delivery of chemotherapy leads to adverse effects, such as chemotherapy induced alopecia (CIA) and chemotherapy-induced peripheral neuropathy (CIPN), which can range from life-altering to life-threatening. Moreover, the economic impact of current cancer chemotherapy is unsustainable and, thus, an alternative therapy for lung cancer need to be investigated. Towards this goal, resveratrol loaded polymeric nanoparticles (NPs) formulated into nanocomposite microparticles (NCMPs) using L-leucine and chitosan were developed for the pulmonary delivery via dry powder inhalation. Resveratrol was loaded into NPs of poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) with sizes ranging between 220-230 nm, which are ideal for uptake into cells. The 5%- and 10% resveratrol-loaded NPs (5% RNP and 10% RNP) had a high encapsulation efficiency of 39 ± 0.12 and 70 ± 0.89% and a drug loading of 78 ± 0.24 µg and 70 ± 0.89 µg (w/w), respectively. The PGA-co-PDL blank NPs (BNP) at 1 mg/mL showed good cytocompatibility in Calu 3 cells with a cell viability of 87.5±4.7% after 24-hour exposure. Meanwhile, the 5% RNP and 10% RNP decreased the IC50 of resveratrol in Calu 3 cells after 24 hours from 213 ± 63 µM to 47 ± 30 µM and 48 ± 12 µM, respectively. This is a reduction in IC50 of up to 78%. The PGA-co-PDL NPs were spray-dried in NCMPs with mass median aerodynamic xxvi diameters (MMADs) between 3.1-4 µm, which is within the ideal range of 1-5 µm for particles to be able to deposit in the deep regions of the lung. Furthermore, the NCMPs showed a slow release profile, with only 25% of resveratrol being released over 24 hours. Lastly, a novel polymer was synthesised which possessed an alkyne that can allow for the attachment of various ligands, including a fluorescent probe to visualise uptake of the NPs. Overall, the obtained results demonstrate that these NPs/NCMPs show promise as pulmonary drug delivery systems for lung cancer.
- Published
- 2020
- Full Text
- View/download PDF
20. MicroRNA nanocarriers for the treatment of chronic obstructive pulmonary disease
- Author
-
Mohamed, A. A., Saleem, I., Hutcheon, G., and Ross, K.
- Subjects
616.2 ,RM Therapeutics. Pharmacology - Abstract
Chronic obstruction pulmonary disease (COPD) is a major cause of morbidity and mortality across the world. COPD is currently the fourth leading cause of death in the world and is predicted to become the third leading cause of chronic illness and death worldwide by 2030. There are several therapeutic strategies to reduce COPD symptoms and complications such as; bronchodilator medications, antibiotics, inhaled corticosteroids and rehabilitation. However, none of the available pharmacological or non-pharmacological treatments for COPD have been shown to delay or correct long-term defects in lung function. Small nucleic acids such as non-coding RNA (ncRNA) and interference microRNA (miRNA) have recently gained attention as a new class of therapeutics for various genetic diseases. Modulation of miRNA expression and function represents a promising strategy for therapeutic intervention in disorders such as inflammatory lung disease including COPD. In this study the aim was to design, formulate and characterise polymeric nanoparticles (NPs) containing miR-146a. This was followed by spray-dying using L-leucine and mannitol to prepare dry powder nanocomposite microparticles (NCMPs) for pulmonary delivery. Anionic and cationic poly (glycerol adipate-co- ω-pentadecalactone), (PGA-co-PDL), NPs were produced using poly (vinyl alcohol) and dioleoyltrimethylammoniumpropane (DOTAP) respectively. The particle size of the anionic NPs was 266.10±20.80 nm and the incorporation of DOTAP resulted in NPs of 244.80±4.40 nm at 15 % DOTAP concentration. The zeta potential (ZP) of 15 % DOTAP NPs was +14.8±0.26 mV. Fluorescently labelled synthetic miRNA (miR-146a) was adsorbed onto the surface of the optimum 15 % DOTAP NPs. The cell viability studies indicated that over 65 % of A549 cells remained viable after 24 h exposure to cationic NPs at a concentration of 1.25 mg/ml. The spray drying process was optimised to produce NCMPs with recovered NPs of 409.7±10.05 nm, yield of 86.05±15.01 % and low moisture content 2.02±0.03 %. The NCMPs produced had a spherical shape and corrugated surface. The in vitro aerosolisation analysis showed a mass mean aerodynamic diameters (MMAD) of less than 6 μm indicating the NCMPs would be deposited in the middle to deep lung region and a fine particle fraction (FPF) of 51.33±2.90 %. Internalisation of miR-146a loaded cationic NPs was observed in A549 cell lines using both fluorescence and confocal microscopy. The miR146a delivered to A549 cells as miR-146a-NPs and miR146a-NCMPs had a dose dependent reduction on target gene repression; interleukin 1 receptor-associated kinase (IRAK1) expression to 40 % and TNF receptor-associated factor (TRAF6) expression to over 20 %. Moreover, the miR-146a biological activity was maintained after spray drying. These findings demonstrate the promise of miR-146a-NPs/NCMPs as a dry powder pulmonary for the treatment of COPD, protecting miR-146a from degradation and enzymatic activity in the lung airways.
- Published
- 2018
- Full Text
- View/download PDF
21. Development of Afatinib lipid nanoparticles targeting non small cell lung cancer
- Author
-
Almurshedi, A., Hutcheon, G., and Saleem, I.
- Subjects
RC0254 Neoplasms. Tumors. Oncology (including Cancer) ,RM Therapeutics. Pharmacology - Abstract
Lung cancer is the most common cause of cancer-associated mortality in males and females globally. Widespread research is currently focused on the development of novel approaches for targeting non small cell lung cancer with different therapeutic nanotechnologies. In this study, a sensitive and selective HPLC method was developed for the quantification of afatinib (AFT) in formulations. Novel drug delivery systems based on cationic (CL) and pH-sensitive liposomes (PSL) for AFT were developed, with different ratios of lipid to AFT, using a film hydration method. The obtained liposomes had a small particle size of less than 50 nm with a low polydispersibilty index and acceptable zeta potential. The highest Encapsulation Efficiency (EE%) of AFT reached 43.20%, 50.20%, and 52.01% for NL (Non targeting liposomes), PSL, CL, respectively at the 1:0.5 ratio of AFT: lipids. The in vitro release study confirmed that all formulations had sustained release profiles in pH 7.4. However, in acidic pH values, PSL exhibited fast release. The stability study, conducted at 4°C and 25°C for 1 month, showed that the characteristics of liposomes in liquid form did not change significantly over this period. In vitro cytotoxicity studies revealed high antitumor activity of PSL on all cell lines at 0.75 μM concentration after 24 h exposure, based on using the Annexin V assay. A proteomics study identified 12 proteins which can be used as biomarkers capable of prediction of treatment response and choice of therapy for two different types of human NSCLC cells (H-1975 and H-1650). Spray drying was used to produce nanocomposite microparticles (NCMPs) using L-leucine and coated using different ratios of chitosan for the optimized PSL NPs. The particles had a corrugated surface except at high CH ratios, where more homogenous and smooth particles with some small indentations were obtained. The powder properties showed good flow properties and reproducible size. Coated NCMPs showed a delayed drug release profile compared to PSL NPs and the best correlation with the Higuchi model. A stability study at 40°C/ 75% ± 5% relative humidity (RH) showed large changes in the drug content for all coated NCMPs powders. Analysis of the in vitro aerosolization performance demonstrated a mass median aerodynamic diameter (MMAD) of 3.24 – 5.85 μm and fine particle fraction (FPF%) of 54.20-33.66%. The particle size of the reconstituted powders was ˂ 100 nm, which is within the size range to be effectively taken up by tumor cells. Assessment of the stability of spray dried liposomes after 3 months of storage at 40 °C/75% RH, showed that fusion and aggregation of the liposomes occurred in all samples tested. The C1NCMPs (lipid: LEU: CH ratio of 1:1.5:0.5) exhibited the highest FPF (51.2%) and fine particle dose (FPD) (40.0 μg of AFT) indicating deep lung deposition. Further cell viability studies of C1 NCMP, at a concentration of 0.75 μM on H-1975 NSCLC cell line showed a good toxicity profile comparable to PSL nanoparticles (NPs). The obtained data indicates that pulmonary delivery of PSL NCMPs is a potential new clinical strategy for better targetability and delivery of AFT for the treatment of lung cancer.
- Published
- 2018
22. The development and evaluation of antibacterial polymer-phyllosilicate composite systems for the treatment of infected wounds
- Author
-
Hamilton, A. R., Gaskell, E., Roberts, M., and Hutcheon, G.
- Subjects
615.7 ,RM Therapeutics. Pharmacology ,RS Pharmacy and materia medica - Abstract
Clays and clay minerals (phyllosilicates) have been used for millennia to treat a range of human maladies, such as infected wounds and diseases of the skin. The unique chemistry of phyllosilicates allows them to support the wound environment and encourage healing. Their physicochemical properties can also be utilised to develop modified drug-release formulations and also enables their incorporation into polymer matrices for the development of advanced wound care materials. By developing novel antibacterial phyllosilicate-polymer composite materials it should be possible to support wound healing, whilst simultaneously treating infections locally to avoid systemic adverse effects and prevent the development of antimicrobial resistance. In this research project the clay minerals kaolin (KN), refined montmorillonite (rMMT), montmorilonite K10 (MMTK10), Laponite® RD (LRD), and Laponite® XL21 (LXL21) were investigated for their differing structure and physicochemical properties. Their ability to adsorb and desorb the antibacterial agents tetracycline (TC), doxycycline (DC) and ciprofloxacin (CIP) was determined through a series of adsorption kinetics and isotherm studies. LRD and LXL21 were shown to have the highest drug-carrying capacity and were also able to relinquish this drug-load to inhibit the proliferation of key wound pathogens; Staphylococcus epidermidis, Propionibacterium acnes, and Pseudomonas aeruginosa. XRD and FTIR analyses demonstrated that these drug molecules could be adsorbed into the interlayer space and edge groups of the Laponite® particles. LXL21-CIP composites were successfully incorporated into alginate polymer matrices through interaction of the exposed edge-groups on LXL21 and the hydroxyl groups of the alginate to produce novel nanocomposite film and foam materials. Selection of candidate materials was initially undertaken qualitatively with the support of a tissue viability nurse at the Royal Liverpool and Broadgreen University Hospitals NHS Trust. Important properties for wound-dressings such as adsorptive capacity, water vapour transmission rate, and keratinocyte compatibility were measured quantitatively and compared to materials already used for wound care in the UK. Both the film and foam materials were shown to have properties that would be beneficial for wound healing and were also able to release CIP in a controlled manner with notable activity against S. epidermidis, P. acnes, and P. aeruginosa. The nanocomposite film formulation developed in this research project showed promise for future clinical applications and future work should be undertaken to further optimise their manufacture and fully characterise their ability to support the healing of infected wounds. Although the nanocomposite foams require further research, the work presented in this thesis suggests they could also be promising materials for wound care applications.
- Published
- 2017
- Full Text
- View/download PDF
23. PULMONARY DELIVERY OF RESVERATROL-LOADED NANOCOMPOSITE MICROPARTICLES TO TREAT LUNG CANCER
- Author
-
Muller, A, Hutcheon, G, Fatokun, A, and Sarker, S
- Subjects
RM - Abstract
Lung cancer was a rare disease in the latter part of the 19th century, but grew into a full-scale epidemic in the 20th century, becoming the most common cause of cancer related death worldwide. Current cancer chemotherapy, involves the administration of cytotoxic drugs that kill all cells exhibiting a high rate of proliferation and regeneration, which is a characteristic of cancer cells, but also non-cancerous cells, such as hair follicles, bone marrow and gastrointestinal tract cells. Therefore, the systemic delivery of chemotherapy leads to adverse effects, such as chemotherapy induced alopecia (CIA) and chemotherapy-induced peripheral neuropathy (CIPN), which can range from life-altering to life-threatening. Moreover, the economic impact of current cancer chemotherapy is unsustainable and, thus, an alternative therapy for lung cancer need to be investigated. Towards this goal, resveratrol loaded polymeric nanoparticles (NPs) formulated into nanocomposite microparticles (NCMPs) using L-leucine and chitosan were developed for the pulmonary delivery via dry powder inhalation. Resveratrol was loaded into NPs of poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) with sizes ranging between 220-230 nm, which are ideal for uptake into cells. The 5%- and 10% resveratrol-loaded NPs (5% RNP and 10% RNP) had a high encapsulation efficiency of 39 ± 0.12 and 70 ± 0.89% and a drug loading of 78 ± 0.24 µg and 70 ± 0.89 µg (w/w), respectively. The PGA-co-PDL blank NPs (BNP) at 1 mg/mL showed good cytocompatibility in Calu 3 cells with a cell viability of 87.5±4.7% after 24-hour exposure. Meanwhile, the 5% RNP and 10% RNP decreased the IC50 of resveratrol in Calu 3 cells after 24 hours from 213 ± 63 µM to 47 ± 30 µM and 48 ± 12 µM, respectively. This is a reduction in IC50 of up to 78%. The PGA-co-PDL NPs were spray-dried in NCMPs with mass median aerodynamic xxvi diameters (MMADs) between 3.1-4 µm, which is within the ideal range of 1-5 µm for particles to be able to deposit in the deep regions of the lung. Furthermore, the NCMPs showed a slow release profile, with only 25% of resveratrol being released over 24 hours. Lastly, a novel polymer was synthesised which possessed an alkyne that can allow for the attachment of various ligands, including a fluorescent probe to visualise uptake of the NPs. Overall, the obtained results demonstrate that these NPs/NCMPs show promise as pulmonary drug delivery systems for lung cancer.
- Published
- 2020
- Full Text
- View/download PDF
24. MicroRNA Nanocarriers for the Treatment of Chronic Obstructive Pulmonary Disease
- Author
-
Mohamed, AA, Saleem, I, Hutcheon, G, and Ross, K
- Subjects
RM ,RM Therapeutics. Pharmacology - Abstract
Chronic obstruction pulmonary disease (COPD) is a major cause of morbidity and mortality across the world. COPD is currently the fourth leading cause of death in the world and is predicted to become the third leading cause of chronic illness and death worldwide by 2030. There are several therapeutic strategies to reduce COPD symptoms and complications such as; bronchodilator medications, antibiotics, inhaled corticosteroids and rehabilitation. However, none of the available pharmacological or non-pharmacological treatments for COPD have been shown to delay or correct long-term defects in lung function. Small nucleic acids such as non-coding RNA (ncRNA) and interference microRNA (miRNA) have recently gained attention as a new class of therapeutics for various genetic diseases. Modulation of miRNA expression and function represents a promising strategy for therapeutic intervention in disorders such as inflammatory lung disease including COPD. In this study the aim was to design, formulate and characterise polymeric nanoparticles (NPs) containing miR-146a. This was followed by spray-dying using L-leucine and mannitol to prepare dry powder nanocomposite microparticles (NCMPs) for pulmonary delivery. Anionic and cationic poly (glycerol adipate-co- ω-pentadecalactone), (PGA-co-PDL), NPs were produced using poly (vinyl alcohol) and dioleoyltrimethylammoniumpropane (DOTAP) respectively. The particle size of the anionic NPs was 266.10±20.80 nm and the incorporation of DOTAP resulted in NPs of 244.80±4.40 nm at 15 % DOTAP concentration. The zeta potential (ZP) of 15 % DOTAP NPs was +14.8±0.26 mV. Fluorescently labelled synthetic miRNA (miR-146a) was adsorbed onto the surface of the optimum 15 % DOTAP NPs. The cell viability studies indicated that over 65 % of A549 cells remained viable after 24 h exposure to cationic NPs at a concentration of 1.25 mg/ml. The spray drying process was optimised to produce NCMPs with recovered NPs of 409.7±10.05 nm, yield of 86.05±15.01 % and low moisture content 2.02±0.03 %. The NCMPs produced had a spherical shape and corrugated surface. The in vitro aerosolisation analysis showed a mass mean aerodynamic diameters (MMAD) of less than 6 µm indicating the NCMPs would be deposited in the middle to deep lung region and a fine particle fraction (FPF) of 51.33±2.90 %. Internalisation of miR-146a loaded cationic NPs was observed in A549 cell lines using both fluorescence and confocal microscopy. The miR146a delivered to A549 cells as miR-146a-NPs and miR146a-NCMPs had a dose dependent reduction on target gene repression; interleukin 1 receptor-associated kinase (IRAK1) expression to 40 % and TNF receptor-associated factor (TRAF6) expression to over 20 %. Moreover, the miR-146a biological activity was maintained after spray drying. These findings demonstrate the promise of miR-146a-NPs/NCMPs as a dry powder pulmonary for the treatment of COPD, protecting miR-146a from degradation and enzymatic activity in the lung airways.
- Published
- 2018
- Full Text
- View/download PDF
25. The development and evaluation of antibacterial polymer-phyllosilicate composite systems for the treatment of infected wounds
- Author
-
Hamilton, AR, Gaskell, E, Roberts, M, and Hutcheon, G
- Subjects
RM ,RS Pharmacy and materia medica ,RM Therapeutics. Pharmacology ,RS - Abstract
Clays and clay minerals (phyllosilicates) have been used for millennia to treat a range of human maladies, such as infected wounds and diseases of the skin. The unique chemistry of phyllosilicates allows them to support the wound environment and encourage healing. Their physicochemical properties can also be utilised to develop modified drug-release formulations and also enables their incorporation into polymer matrices for the development of advanced wound care materials. By developing novel antibacterial phyllosilicate-polymer composite materials it should be possible to support wound healing, whilst simultaneously treating infections locally to avoid systemic adverse effects and prevent the development of antimicrobial resistance. In this research project the clay minerals kaolin (KN), refined montmorillonite (rMMT), montmorilonite K10 (MMTK10), Laponite® RD (LRD), and Laponite® XL21 (LXL21) were investigated for their differing structure and physicochemical properties. Their ability to adsorb and desorb the antibacterial agents tetracycline (TC), doxycycline (DC) and ciprofloxacin (CIP) was determined through a series of adsorption kinetics and isotherm studies. LRD and LXL21 were shown to have the highest drug-carrying capacity and were also able to relinquish this drug-load to inhibit the proliferation of key wound pathogens; Staphylococcus epidermidis, Propionibacterium acnes, and Pseudomonas aeruginosa. XRD and FTIR analyses demonstrated that these drug molecules could be adsorbed into the interlayer space and edge groups of the Laponite® particles. LXL21-CIP composites were successfully incorporated into alginate polymer matrices through interaction of the exposed edge-groups on LXL21 and the hydroxyl groups of the alginate to produce novel nanocomposite film and foam materials. Selection of candidate materials was initially undertaken qualitatively with the support of a tissue viability nurse at the Royal Liverpool and Broadgreen University Hospitals NHS Trust. Important properties for wound-dressings such as adsorptive capacity, water vapour transmission rate, and keratinocyte compatibility were measured quantitatively and compared to materials already used for wound care in the UK. Both the film and foam materials were shown to have properties that would be beneficial for wound healing and were also able to release CIP in a controlled manner with notable activity against S. epidermidis, P. acnes, and P. aeruginosa. The nanocomposite film formulation developed in this research project showed promise for future clinical applications and future work should be undertaken to further optimise their manufacture and fully characterise their ability to support the healing of infected wounds. Although the nanocomposite foams require further research, the work presented in this thesis suggests they could also be promising materials for wound care applications.
26. Development of Afatinib lipid nanoparticles targeting non small cell lung cancer
- Author
-
Almurshedi, A, Hutcheon, G, and Saleem, I
- Subjects
RC0254 ,RM - Abstract
Lung cancer is the most common cause of cancer-associated mortality in males and females globally. Widespread research is currently focused on the development of novel approaches for targeting non small cell lung cancer with different therapeutic nanotechnologies. In this study, a sensitive and selective HPLC method was developed for the quantification of afatinib (AFT) in formulations. Novel drug delivery systems based on cationic (CL) and pH-sensitive liposomes (PSL) for AFT were developed, with different ratios of lipid to AFT, using a film hydration method. The obtained liposomes had a small particle size of less than 50 nm with a low polydispersibilty index and acceptable zeta potential. The highest Encapsulation Efficiency (EE%) of AFT reached 43.20%, 50.20%, and 52.01% for NL (Non targeting liposomes), PSL, CL, respectively at the 1:0.5 ratio of AFT: lipids. The in vitro release study confirmed that all formulations had sustained release profiles in pH 7.4. However, in acidic pH values, PSL exhibited fast release. The stability study, conducted at 4°C and 25°C for 1 month, showed that the characteristics of liposomes in liquid form did not change significantly over this period. In vitro cytotoxicity studies revealed high antitumor activity of PSL on all cell lines at 0.75 µM concentration after 24 h exposure, based on using the Annexin V assay. A proteomics study identified 12 proteins which can be used as biomarkers capable of prediction of treatment response and choice of therapy for two different types of human NSCLC cells (H-1975 and H-1650). Spray drying was used to produce nanocomposite microparticles (NCMPs) using L-leucine and coated using different ratios of chitosan for the optimized PSL NPs. The particles had a corrugated surface except at high CH ratios, where more homogenous and smooth particles with some small indentations were obtained. The powder properties showed good flow properties and reproducible size. Coated NCMPs showed a delayed drug release profile compared to PSL NPs and the best correlation with the Higuchi model. A stability study at 40°C/ 75% ± 5% relative humidity (RH) showed large changes in the drug content for all coated NCMPs powders. Analysis of the in vitro aerosolization performance demonstrated a mass median aerodynamic diameter (MMAD) of 3.24 – 5.85 µm and fine particle fraction (FPF%) of 54.20-33.66%. The particle size of the reconstituted powders was ˂ 100 nm, which is within the size range to be effectively taken up by tumor cells. Assessment of the stability of spray dried liposomes after 3 months of storage at 40 °C/75% RH, showed that fusion and aggregation of the liposomes occurred in all samples tested. The C1NCMPs (lipid: LEU: CH ratio of 1:1.5:0.5) exhibited the highest FPF (51.2%) and fine particle dose (FPD) (40.0 µg of AFT) indicating deep lung deposition. Further cell viability studies of C1 NCMP, at a concentration of 0.75 μM on H-1975 NSCLC cell line showed a good toxicity profile comparable to PSL nanoparticles (NPs). The obtained data indicates that pulmonary delivery of PSL NCMPs is a potential new clinical strategy for better targetability and delivery of AFT for the treatment of lung cancer
27. A novel 4-dimensional live-cell imaging system to study leukocyte-endothelial dynamics in ANCA-associated vasculitis.
- Author
-
Walls CA, Basu N, Hutcheon G, Erwig LP, Little MA, and Kidder D
- Subjects
- Adult, Aged, Cells, Cultured, Endothelium metabolism, Female, Human Umbilical Vein Endothelial Cells, Humans, Immunoglobulin G metabolism, Leukocytes metabolism, Leukocytes pathology, Male, Middle Aged, Monocytes pathology, Neutrophil Activation physiology, Neutrophils metabolism, Receptor, Anaphylatoxin C5a metabolism, Tumor Necrosis Factor-alpha metabolism, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis metabolism, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis pathology, Antibodies, Antineutrophil Cytoplasmic metabolism, Endothelium pathology, Neutrophils pathology
- Abstract
Neutrophils, monocytes and the endothelium are critical to ANCA-associated vasculitis (AAV) pathogenesis. This study aimed to develop a 4-dimensional (4D) live-cell imaging system that would enable investigation of spatial and temporal dynamics of these cells in health and disease. We further aimed to validate this system using autologous donor serum from AAV patients and polyclonal ANCA IgG, as well as exploring its potential in the pre-clinical testing of putative therapeutic compounds. Neutrophils and monocytes were isolated from peripheral venous blood of AAV patients or healthy controls and co-incubated on an endothelial monolayer in the presence of autologous serum. Alternatively, polyclonal ANCA IgG was used, following TNF-α priming, and imaged in 4-dimensions for 3 h using a spinning disc confocal microscope. Volocity 6.3
® analysis software was used for quantification of leukocyte dynamics. The use of autologous serum resulted in increased neutrophil degranulation ( p = .002), transmigration ( p = .0096) and monocyte transcellular transmigration ( p = .0013) in AAV patients. Polyclonal MPO-ANCA IgG induced neutrophil degranulation ( p < .001) in this system. C5aR1 antagonism reduced neutrophil degranulation ( p < .0002). We have developed a novel 4D in vitro system that allows accurate quantification of multiple neutrophil- and monocyte-endothelial interactions in AAV in a single assay. This system has the potential to highlight dynamics key to pathophysiology of disease, as well investigating the impact of potential therapeutics on these functions.- Published
- 2020
- Full Text
- View/download PDF
28. Metabolic and Structural Skeletal Muscle Health in Systemic Lupus Erythematosus-Related Fatigue: A Multimodal Magnetic Resonance Imaging Study.
- Author
-
Cheung SM, Keenan K, Senn N, Hutcheon G, Chan K, Erwig L, Schrepf A, Dospinescu P, Gray S, Waiter G, He J, and Basu N
- Subjects
- Adult, Case-Control Studies, Fatigue etiology, Fatigue physiopathology, Female, Humans, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic physiopathology, Magnetic Resonance Imaging methods, Male, Muscle, Skeletal diagnostic imaging, Diffusion Tensor Imaging methods, Fatigue diagnosis, Lupus Erythematosus, Systemic complications, Magnetic Resonance Spectroscopy methods, Multimodal Imaging, Muscle Strength physiology, Muscle, Skeletal metabolism
- Abstract
Objective: To investigate the potential structural and metabolic role of skeletal muscle in systemic lupus erythematosus (SLE)-related fatigue., Methods: A case-control, multimodal magnetic resonance imaging (MRI) study was conducted. Cases were patients with inactive SLE who reported chronic fatigue. Controls were age- and sex-matched healthy members of the general population. Patients were clinically characterized and then underwent a 3T whole-body MRI scan. Resting and dynamic
31 P MRI spectroscopy of the calf muscles was applied, from which phosphocreatine (PCr) recovery halftime, a marker of mitochondrial dysfunction, was computed. In addition, microstructural sequences (T1-weighted anatomic images, T2 mapping, and diffusion tensor imaging) were acquired. Descriptive statistics evaluated group differences and within-case physical fatigue correlations were explored., Results: Of the 37 recruits (mean age 43.8 years, 89.2% female), cases (n = 19) reported higher levels of physical fatigue, pain, depression, and sleep disturbance compared to the control group (P < 0.0001). PCr was greater (P = 0.045) among cases (mean ± SD 33.0 ± 9.0 seconds) compared to controls (mean ± SD 27.1 ± 6.6 seconds). No microstructural group differences were observed. Within cases, physical fatigue did not correlate with PCr (r = -0.28, P = 0.25)., Conclusion: We report preliminary data demonstrating greater skeletal muscle mitochondrial dysfunction among fatigued patients with SLE compared to healthy controls., (© 2019, American College of Rheumatology.)- Published
- 2019
- Full Text
- View/download PDF
29. Incidence, Risks, and Types of Infections in Pediatric Long-term Care Facilities.
- Author
-
Saiman L, Maykowski P, Murray M, Cohen B, Neu N, Jia H, Hutcheon G, Simpser E, Mosiello L, Alba L, and Larson E
- Subjects
- Adolescent, Child, Cohort Studies, Female, Humans, Incidence, Male, New York epidemiology, Prospective Studies, Risk Factors, Infections epidemiology, Long-Term Care statistics & numerical data
- Abstract
Importance: The population of infants, children, and adolescents cared for at pediatric long-term care facilities is increasing in complexity and size and thus consumes substantial health care resources. Infections are a significant cause of morbidity and mortality in this population, but few recent data describe their incidence and effects., Objectives: To describe the types of infections diagnosed in residents of pediatric long-term care facilities, calculate infection rates, and identify risk factors for respiratory tract infections (RTIs)., Design, Setting, and Participants: This prospective cohort study, which was part of a larger trial called Keep It Clean for Kids, was conducted from September 1, 2012, to December 31, 2015, at 3 pediatric long-term care facilities in New York. Residents of the facilities who were 21 years or younger and either residents or admitted during the study period (n = 717) were enrolled in the study. Medical records were reviewed to identify infections diagnosed by site clinicians., Main Outcomes and Measures: Incidence of infections, such as RTIs; skin and soft-tissue infections; chronic comorbid conditions, including neurologic and respiratory disorders; and device use, including gastrostomy tubes and tracheostomies, was determined. Risk factors for RTIs were assessed by generalized linear mixed method regression modeling., Results: The 717 residents had a median (interquartile range) age at enrollment of 2.6 (0.4-9.1) years; 358 (49.9%) were male. Four hundred twenty-eight residents (59.7%) had feeding tubes and 215 (30.0%) had tracheostomies. Most chronic comorbid conditions were musculoskeletal or ambulation (532 residents [74.2%]), neurologic (505 [70.4%]), respiratory (361 [50.3%]), and gastrointestinal (230 [32.1%]) disorders, and 460 residents (64.2%) had 4 or more chronic comorbid conditions. Site clinicians diagnosed 2052 infections during the 3-year study period. Respiratory tract infections were most common and were diagnosed in 1291 residents (62.9%). The overall infection rate was 5.3 infections per 1000 resident-days, and RTI rates were 3.3 infections per 1000 resident-days. Overall infection rates and rates of RTI, skin and soft-tissue infection, urinary tract infection, and bloodstream infection varied among the 3 sites. In the multivariable model, younger age (incidence rate ratio [IRR], 1.05; 95% CI, 1.03-1.06), increased number of chronic comorbid conditions (IRR, 1.12; 95% CI, 1.06-1.19), and the use of feeding tubes (IRR, 1.34; 95% CI, 1.03-1.64) and tracheostomies (IRR, 1.40; 95% CI, 1.17-1.69) were associated with RTIs., Conclusions and Relevance: In this study, RTIs were the most common infections diagnosed, but modifiable risk factors for RTIs were not identified. Future work should focus on optimizing infection prevention and control strategies to reduce infections, particularly RTIs, in the pediatric long-term care population.
- Published
- 2017
- Full Text
- View/download PDF
30. Is hand hygiene frequency associated with the onset of outbreaks in pediatric long-term care?
- Author
-
Cohen B, Murray M, Jia H, Jackson O, Saiman L, Neu N, Hutcheon G, and Larson E
- Subjects
- Adolescent, Case-Control Studies, Child, Child, Preschool, Cross Infection epidemiology, Female, Gastroenteritis epidemiology, Gastroenteritis prevention & control, Humans, Infant, Infant, Newborn, Male, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control, Virus Diseases epidemiology, Young Adult, Cross Infection prevention & control, Disease Outbreaks, Hand Hygiene methods, Hospitals, Pediatric, Long-Term Care, Virus Diseases prevention & control
- Abstract
Background: Studies in adult long-term care facilities (LTCFs) have shown a correlation between hand hygiene (HH) and viral outbreak reduction, but no such studies have been conducted in pediatric LTCFs where the epidemiology of viral pathogens is different., Methods: We compared electronically monitored facility-wide HH frequency in the weeks immediately prior to outbreaks of acute respiratory or gastrointestinal infections versus control weeks in a 137-bed pediatric LTCF from October 2012-August 2015. Control weeks were the 8-14 day (control 1) and 15-21 day (control 2) periods prior to the onset of each outbreak., Results: There was no difference in HH frequency in the weeks leading up to the outbreaks versus control weeks (odds ratio [OR], 1.0; 95% confidence interval CI, 1.00-1.001 using control 1 and OR, 1.0; 95% CI, 1.00-1.001 using control 2)., Conclusions: Our findings differed from those in adult LTFCs, possibly because of the greater contact between residents and staff in the pediatric setting, increased susceptibility to viral pathogens because of immunologic immaturity, or differences in the types of pathogens prevalent in each setting. Although HH may be important for limiting the number of residents infected during outbreaks, we found no association between HH frequency and subsequent outbreak onset., (Copyright © 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
31. Impact of Infection Prevention and Control Initiatives on Acute Respiratory Infections in a Pediatric Long-Term Care Facility.
- Author
-
Murray MT, Jackson O, Cohen B, Hutcheon G, Saiman L, Larson E, and Neu N
- Subjects
- Acute Disease, Adolescent, Child, Child, Preschool, Cross Infection epidemiology, Humans, Infant, Length of Stay statistics & numerical data, Long-Term Care statistics & numerical data, Respiratory Tract Infections epidemiology, Young Adult, Cross Infection prevention & control, Long-Term Care methods, Respiratory Tract Infections prevention & control
- Abstract
We evaluated the collective impact of several infection prevention and control initiatives aimed at reducing acute respiratory infections (ARIs) in a pediatric long-term care facility. ARIs did not decrease overall, though the proportion of infections associated with outbreaks and average number of cases per outbreak decreased. Influenza rates decreased significantly. Infect Control Hosp Epidemiol 2016;37:859-862., Competing Interests: Potential conflicts of interest: All authors report no conflicts of interest relevant to this article.
- Published
- 2016
- Full Text
- View/download PDF
32. Direct costs of acute respiratory infections in a pediatric long-term care facility.
- Author
-
Murray MT, Heitkemper E, Jackson O, Neu N, Stone P, Cohen B, Saiman L, Hutcheon G, and Larson EL
- Subjects
- Adolescent, Child, Child, Preschool, Humans, Infant, Infant, Newborn, New York City epidemiology, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control, Cost of Illness, Long-Term Care economics, Respiratory Tract Infections economics
- Abstract
Acute respiratory tract infections (ARI) are a major burden in pediatric long-term care. We analyzed the financial impact of ARI in 2012-2013. Costs associated with ARI during the respiratory viral season were ten times greater than during the non-respiratory viral season, $31 224 and $3242 per 1000 patient-days, respectively (P < 0·001). ARI are burdensome for pediatric long-term care facilities not only because of the associated morbidity and mortality, but also due to the great financial costs of prevention., (© 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
33. Developing Case Definitions for Health Care-Associated Infections for Pediatric Long-Term Care Facilities.
- Author
-
Murray MT, Neu N, Cohen B, Hutcheon G, Simpser E, Larson E, and Saiman L
- Subjects
- Child, Cross Infection epidemiology, Female, Humans, Infection Control methods, Male, New York epidemiology, Pilot Projects, Population Surveillance, Retrospective Studies, Cross Infection diagnosis, Cross Infection therapy, Long-Term Care
- Published
- 2015
- Full Text
- View/download PDF
34. Infection prevention and control practices in pediatric long-term care facilities.
- Author
-
Murray MT, Cohen B, Neu N, Hutcheon G, Simpser E, Larson E, and Saiman L
- Subjects
- Adolescent, Child, Child, Preschool, Humans, Infant, Practice Guidelines as Topic, Cross Infection prevention & control, Infection Control methods, Long-Term Care methods
- Abstract
Pediatric long-term care facilities (pLTCFs) provide for children with chronic, complex medical needs and therefore face unique challenges for infection prevention and control (IP&C). At a conference in 2012, pLTCF providers reported IP&C issues of greatest concern in a survey. Major concerns included the lack of IP&C best practice guidelines, multidrug-resistant bacteria, and viral respiratory infections. Best practice guidelines for IP&C specific to pLTCF populations should be developed and evaluated., (Copyright © 2014 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
35. Epidemiology of human metapneumovirus in a pediatric long-term care facility.
- Author
-
Neu N, Plaskett T, Hutcheon G, Murray M, Southwick KL, and Saiman L
- Subjects
- Adenoviridae Infections diagnosis, Adenoviridae Infections epidemiology, Adenoviridae Infections prevention & control, Adolescent, Child, Child, Preschool, Cross Infection diagnosis, Cross Infection prevention & control, Female, Humans, Infant, Infection Control, Influenza A virus isolation & purification, Influenza, Human diagnosis, Influenza, Human epidemiology, Influenza, Human prevention & control, Male, New York City, Paramyxoviridae Infections diagnosis, Paramyxoviridae Infections prevention & control, Patient Transfer statistics & numerical data, Respiratory Syncytial Virus Infections diagnosis, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Retrospective Studies, Young Adult, Cross Infection epidemiology, Disease Outbreaks prevention & control, Disease Outbreaks statistics & numerical data, Metapneumovirus isolation & purification, Paramyxoviridae Infections epidemiology, Residential Facilities
- Abstract
Background: Viral respiratory pathogens cause outbreaks in pediatric long-term care facilities (LTCFs), but few studies have used viral diagnostic testing to identify the causative pathogens. We describe the use of such testing during a prolonged period of respiratory illness and elucidate the epidemiology of human metapneumovirus (hMPV) at our LTCF., Design: Retrospective study of influenza-like illness (ILI)., Setting: A 136-bed pediatric LTCF from January 1 through April 30, 2010., Methods: The ILI case definition included fever, cough, change in oropharyngeal secretions, increase in oxygen requirement, and/or wheezing., Results: During the study period, 69 episodes of ILI occurred in 61 (41%) of 150 residents. A viral pathogen was detected in 27 (39%) of the episodes, including respiratory syncytial virus (RSV) (n = 3), influenza A virus (not typed; n = 2), parainfluenza virus (n =2), adenovirus (n = 1), and hMPV (n = 19). Twenty-seven of the residents with ILI (44%) required transfer to acute care hospitals (mean length of hospitalization, 12 days; range, 3-47 days). Residents with tracheostomies were more likely to have ILI (adjusted odds ratio [OR], 3.99 [95% confidence interval {CI}, 1.87-8.53]; P = .0004). The mortality rate for residents with ILI was 1.6%. Residents with hMPV were younger (P = .03), more likely to be transferred to an acute care facility (OR, 3.73 [95% CI, 1.17-11.95]; P = .02), and less likely to have a tracheostomy (adjusted OR, 0.19 [95% CI, 0.047-0.757]; P = .02 )., Discussion: Diverse pathogens, most notably hMPV, caused ILI in our pediatric LTCF during a prolonged period of time. Viral testing was helpful in characterizing the epidemiology of ILI in this population.
- Published
- 2012
- Full Text
- View/download PDF
36. Poly(glycerol adipate-co-ω-pentadecalactone) spray-dried microparticles as sustained release carriers for pulmonary delivery.
- Author
-
Tawfeek H, Khidr S, Samy E, Ahmed S, Murphy M, Mohammed A, Shabir A, Hutcheon G, and Saleem I
- Subjects
- Aerosols, Cell Line, Cell Survival drug effects, Delayed-Action Preparations pharmacokinetics, Drug Carriers chemical synthesis, Drug Carriers toxicity, Drug Compounding methods, Epithelial Cells drug effects, Humans, Microscopy, Electron, Scanning, Microspheres, Molecular Structure, Particle Size, Polyesters chemical synthesis, Polyesters toxicity, Powders, Solubility, Surface Properties, Tissue Distribution, Delayed-Action Preparations administration & dosage, Drug Carriers chemistry, Lung metabolism, Polyesters chemistry
- Abstract
Purpose: The aim of this work was to optimize biodegradable polyester poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL, microparticles as sustained release (SR) carriers for pulmonary drug delivery., Methods: Microparticles were produced by spray drying directly from double emulsion with and without dispersibility enhancers ((L)-arginine and (L)-leucine) (0.5-1.5%w/w) using sodium fluorescein (SF) as a model hydrophilic drug., Results: Spray-dried microparticles without dispersibility enhancers exhibited aggregated powders leading to low fine particle fraction (%FPF) (28.79 ± 3.24), fine particle dose (FPD) (14.42 ± 1.57 μg), with a mass median aerodynamic diameter (MMAD) 2.86 ± 0.24 μm. However, (L)-leucine was significantly superior in enhancing the aerosolization performance ((L-)arginine:%FPF 27.61 ± 4.49-26.57 ± 1.85; FPD 12.40 ± 0.99-19.54 ± 0.16 μg and MMAD 2.18 ± 0.35-2.98 ± 0.25 μm, (L)-leucine:%FPF 36.90 ± 3.6-43.38 ± 5.6; FPD 18.66 ± 2.90-21.58 ± 2.46 μg and MMAD 2.55 ± 0.03-3.68 ± 0.12 μm). Incorporating (L)-leucine (1.5%w/w) reduced the burst release (24.04 ± 3.87%) of SF compared to unmodified formulations (41.87 ± 2.46%), with both undergoing a square root of time (Higuchi's pattern) dependent release. Comparing the toxicity profiles of PGA-co-PDL with (L)-leucine (1.5%w/w) (5 mg/ml) and poly(lactide-co-glycolide), (5 mg/ml) spray-dried microparticles in human bronchial epithelial 16HBE14o- cell lines, resulted in cell viability of 85.57 ± 5.44 and 60.66 ± 6.75%, respectively, after 72 h treatment., Conclusion: The above data suggest that PGA-co-PDL may be a useful polymer for preparing SR microparticle carriers, together with dispersibility enhancers, for pulmonary delivery.
- Published
- 2011
- Full Text
- View/download PDF
37. Emerging methods and tools for environmental risk assessment, decision-making, and policy for nanomaterials: summary of NATO Advanced Research Workshop.
- Author
-
Linkov I, Steevens J, Adlakha-Hutcheon G, Bennett E, Chappell M, Colvin V, Davis JM, Davis T, Elder A, Foss Hansen S, Hakkinen PB, Hussain SM, Karkan D, Korenstein R, Lynch I, Metcalfe C, Ramadan AB, and Satterstrom FK
- Abstract
Nanomaterials and their associated technologies hold promising opportunities for the development of new materials and applications in a wide variety of disciplines, including medicine, environmental remediation, waste treatment, and energy conservation. However, current information regarding the environmental effects and health risks associated with nanomaterials is limited and sometimes contradictory. This article summarizes the conclusions of a 2008 NATO workshop designed to evaluate the wide-scale implications (e.g., benefits, risks, and costs) of the use of nanomaterials on human health and the environment. A unique feature of this workshop was its interdisciplinary nature and focus on the practical needs of policy decision makers. Workshop presentations and discussion panels were structured along four main themes: technology and benefits, human health risk, environmental risk, and policy implications. Four corresponding working groups (WGs) were formed to develop detailed summaries of the state-of-the-science in their respective areas and to discuss emerging gaps and research needs. The WGs identified gaps between the rapid advances in the types and applications of nanomaterials and the slower pace of human health and environmental risk science, along with strategies to reduce the uncertainties associated with calculating these risks.
- Published
- 2009
- Full Text
- View/download PDF
38. Synthesis and evaluation of novel polyester-ibuprofen conjugates for modified drug release.
- Author
-
Thompson CJ, Hansford D, Munday DL, Higgins S, Rostron C, and Hutcheon GA
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal chemical synthesis, Calorimetry, Differential Scanning, Chromatography, Gel, Chromatography, High Pressure Liquid, Delayed-Action Preparations, Ibuprofen chemical synthesis, Magnetic Resonance Spectroscopy, Polyesters chemical synthesis, Spectrophotometry, Infrared, Anti-Inflammatory Agents, Non-Steroidal chemistry, Chemistry, Pharmaceutical methods, Ibuprofen chemistry, Polyesters chemistry
- Abstract
Ibuprofen was conjugated at different levels to a novel polyester, poly(glycerol-adipate-co-omega-pentadecalactone) (PGA-co-PL), via an ester linkage to form a prodrug. The conjugates were characterized by differential scanning calorimetry (DSC), nuclear magnetic resonance (NMR), infrared (IR), gel permeation chromatography (GPC), ultraviolet (UV), and high-performance liquid chromatography (HPLC). The conjugates had a molecular weight between 18 and 24 kDa, and there was a suppression of the free hydroxyl groups within the conjugated polymer. DSC scans showed a lowering of the melting point (T(m)) when compared with the polyester alone and a difference in the number and area of T(m) peaks. Drug release studies showed an initial burst release (13-18%) followed thereafter by very slow release (maximum 35% after 18 days). Continuous work may produce ester-linked conjugates that are sufficiently labile to allow for complete release of ibuprofen over the time period studied.
- Published
- 2008
- Full Text
- View/download PDF
39. Regulatory considerations for biotechnology-derived animals in Canada.
- Author
-
Kochhar HP, Adlakha-Hutcheon G, and Evans BR
- Subjects
- Animal Welfare, Animals, Canada, Consumer Product Safety, Animals, Genetically Modified, Biotechnology legislation & jurisprudence, Environment
- Abstract
Regulatory initiatives relating to biotechnology-derived livestock have focused on animal health, environmental impact, and the general concept of the safety of the food and by-products derived from such animals. Existing regulatory frameworks have been stretched to accommodate these emerging concerns. Public concerns and the expectations of society mean that the regulatory infrastructure is subject to a high level of scrutiny and that regulations are expected to maintain a clear level of confidence, transparency and effectiveness. A sound regulatory regime should be 'neutral', neither 'facilitating' nor 'restricting' the approval of products or by-products derived from biotechnology-derived animals.
- Published
- 2005
40. The archaeal twin-arginine translocation pathway.
- Author
-
Hutcheon GW and Bolhuis A
- Subjects
- Amino Acid Sequence, Archaea classification, Archaeal Proteins chemistry, Bacteria metabolism, Biological Transport, Chloroplasts metabolism, Molecular Sequence Data, Sequence Alignment, Sequence Homology, Amino Acid, Archaea metabolism, Archaeal Proteins metabolism, Arginine metabolism
- Abstract
The twin-arginine translocation (Tat) pathway is a system with the unique ability to export proteins in a fully folded conformation. Its main components are TatA, TatB and TatC, all of which are required for Tat-dependent export. The Tat pathway is found in several Archaea, and in most of them a moderate number of predicted Tat-dependent substrates are present. Putative substrates include those binding cofactors such as iron-sulphur clusters and molybdopterin. In these Archaea, the role of the Tat pathway seems to be similar to that of bacteria: the export of a small subset of proteins that fold before translocation across the cytoplasmic membrane. The exception to this is the Tat system of the halophilic archaeon Halobacterium sp. NRC-1. In this organism, the majority of extra-cytoplasmic proteins are predicted to use the Tat pathway, which is, most likely, a specific adaptation to its particular lifestyle in highly saline conditions.
- Published
- 2003
- Full Text
- View/download PDF
41. Measuring enzyme motility in organic media using novel H-D exchange methodology.
- Author
-
Hutcheon GA, Parker MC, and Moore BD
- Subjects
- Air, Bacillus enzymology, Deuterium, Freeze Drying, Hexanes, Hydrogen, In Vitro Techniques, Magnetic Resonance Spectroscopy, Protein Conformation, Solvents, Subtilisins isolation & purification, Biotechnology methods, Enzymes chemistry
- Abstract
A novel deuterium ((2)H) NMR technique as developed for measuring the total number of deuterons exchanged by lyophilised protein samples following hydrogen-deuterium (H-D) exchange. Using this methodology differences in the H-D exchange behaviour of the proteolytic enzyme subtilisin Carlsberg hydrated either in air or an organic solvent were probed as a function of hydration. At low thermodynamic water activity (a(w)), the degree of H-D exchange increased rapidly with hydration (from anhydrous to a(w) 0.22). At a(w) 0.22, subtilisin powders hydrated in air were found to have reached an H-D exchange level comparable to that found upon aqueous dissolution and in agreement with previous studies using lysozyme. Lyophilised subtilisin hydrated in either dichloromethane (DCM) or diisopropyl ether (DIPE) showed a pattern of exchange (vs. a(w)) comparable to that found for powders hydrated in air. However, subtilisin hydrated in n-hexane showed a significant reduction in H-D exchange at all a(w) studied. Control experiments demonstrated that the reduction in H-D exchange observed for subtilisin in n-hexane was not a kinetic effect. This lower level of exchange in n-hexane implies that hydrated subtilisin Carlsberg has a lower conformational motility and more rigid protein matrix., (Copyright 2000 John Wiley & Sons, Inc. Biotechnol Bioeng 70: 262-269, 2000.)
- Published
- 2000
42. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity.
- Author
-
Adlakha-Hutcheon G, Bally MB, Shew CR, and Madden TD
- Subjects
- Animals, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents therapeutic use, Cell Line, Drug Carriers, Female, Humans, Liposomes, Mice, Mitoxantrone pharmacokinetics, Mitoxantrone therapeutic use, Neoplasms drug therapy, Tissue Distribution, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Mitoxantrone pharmacology, Neoplasms metabolism
- Abstract
Programmable fusogenic vesicles (PFVs) are lipid-based drug-delivery systems that exhibit time-dependent destabilization. The rate at which this destabilization occurs is determined by the exchange rate of a bilayer-stabilizing component, polyethylene glycol-phosphatidylethanolamine (PEG-PE) from the vesicle surface. This exchange rate is controlled, in turn, by the acyl chain composition of the PEG-PE. We describe in vitro and in vivo studies using PFVs as delivery vehicles for the anticancer drug mitoxantrone. We demonstrate that the PEG-PE acyl composition determined the rate at which PFVs are eliminated from plasma after intravenous administration, and the rate of mitoxantrone leakage from PFV. The nature of the PEG-PE component also determined the antitumor efficacy of mitoxantrone-loaded PFV in murine and human in murine and human xenograft tumor models. Increased circulation time and improved activity were obtained for PFV containing PEG-PE with an 18-carbon acyl chain length, as a result of slower vesicle destabilization.
- Published
- 1999
- Full Text
- View/download PDF
43. Human T-cell lymphotropic virus type III (HTLV-III) embryopathy. A new dysmorphic syndrome associated with intrauterine HTLV-III infection.
- Author
-
Marion RW, Wiznia AA, Hutcheon G, and Rubinstein A
- Subjects
- Acquired Immunodeficiency Syndrome complications, Anthropometry, Child, Preschool, Deltaretrovirus immunology, Female, Fetal Growth Retardation etiology, Growth Disorders etiology, Humans, Infant, Male, Pregnancy, Acquired Immunodeficiency Syndrome congenital, Antibodies, Viral analysis, Facial Bones abnormalities, Fetal Diseases microbiology, Retroviridae Infections microbiology, Skull abnormalities
- Abstract
Twenty infants and children with positive serologic tests for the human T-cell lymphotropic virus type III (HTLV-III) were noted to have similar features including growth failure (75%), microcephaly (70%), and craniofacial abnormalities consisting of ocular hypertelorism (50%); prominent box-like appearance of the forehead (75%); flat nasal bridge (70%); mild upward or downward obliquity of the eyes (65%); long palpebral fissures with blue sclerae (60%); short nose with flattened columella and well-formed, triangular philtrum (65%); and patulous lips (60%). These features constitute a new and distinct dysmorphic syndrome, the HTLV-III embryopathy.
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.